The authorities of each country authorize with their regulatory bodies if a drug or vaccine, in this case, is first safe and second effective. It is difficult for everyone to agree on exactly the same thing, Alejandro Macías, infectologist and czar of the AH1N1 epidemic in 2009, told the newspaper Excelsior.

“In the United States, for example, the decision will be biased towards the products of its nation, as it happens that when a country establishes the guidelines to enter its territory, it can say that they authorize only vaccines, in which It has the tools to guarantee its safety and efficacy. There they have considered that neither the CansinoBio nor Gamaleya vaccine, for example, have enough information to authorize it in their territory.”, Explained Macías.

One of the recommendations that made Dr. Macías to the Mexican authorities, to guarantee that the vaccines from the laboratories approved in our territory have sufficient information on their safety and effectiveness (like that of CansinoBio, which has been one of the most questioned) is to request the data from the company.

“I believe that the company is responsible for providing the results of the studies that are being carried out in various parts of the world and integrating the data of the CansinoBio vaccine researchers to report its effectiveness, even in a preliminary way without the need for complete Phase III”, He expressed.

(With information from OMS and Excelsior)

fbq(‘init’, ‘168272650436946’);
fbq(‘track’, ‘ViewContent’);

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more